Table 3.
Comparison | Excluding Breast Cancer Subtype | Including Breast Cancer Subtype | ||
---|---|---|---|---|
OR (95% CI) | P | OR (95% CI) | P | |
Histology | ||||
Ductal vs others | 2.01 (1.07‐3.95) | .03 | 1.78 (0.94‐3.55) | .08 |
Initial stage | ||||
II vs I | 1.32 (0.66‐2.73) | .02 | 1.24 (0.61‐2.58) | .03 |
III vs I | 2.26 (1.08‐4.88) | 1.95 (0.91‐4.26) | ||
IV vs I | 3.17 (1.37‐7.53) | 3.13 (1.34‐7.49) | ||
BRCA status | ||||
BRCA1 carrier vs noncarrier | 3.05 (1.36‐6.89) | .001a | 2.11 (0.89‐4.98) | .005b |
BRCA2 carrier vs noncarrier | 3.11 (1.43‐6.81) | 3.33 (1.51‐7.38) | ||
Breast cancer subtype | ||||
TNBC vs others | — | 2.24 (1.22‐4.09) | .01 |
Abbreviations: OR, odds ratio; TNBC, triple‐negative breast cancer.
Step‐down Wald tests were used with Bonferonni correction (BRCA1 mutation, corrected P = .01; BRCA2 mutation, corrected P = .008).
Step‐down Wald tests were used with Bonferonni correction (BRCA1 mutation, corrected P = .18; BRCA2 mutation, corrected P = .006).